SAN FRANCISCO, Feb. 25, 2020 /PRNewswire/ -- Pinpoint Science Inc. today announced a strategic collaboration with Analog Devices, Inc. to
advance the development and manufacture of novel nanosensor diagnostics
that aim to deliver highly accurate results in under a minute. Pinpoint
Science, a startup based in the San Francisco Bay Area,
and Analog Devices will work together to develop and mature this new
technology that will endeavor to transform the way infectious diseases
are diagnosed around the world. Pinpoint's nanosensors, developed with
the advanced fabrication capabilities of ADI, will target low-cost,
handheld diagnostics and strive to provide results in under a minute
with lab test level accuracy.
With the threat of the novel Covid-19 coronavirus concerning health
officials globally, there is urgent need for better methods of mass
screening to contain the spread of the virus. Today only scanning
foreheads for fever is widely used for screening, but this cannot detect
asymptomatic or presymptomatic infections, nor can it distinguish the
novel coronavirus from other respiratory illnesses. Other coronavirus
diagnostic tests under development don't work for mass screening:
they're essential to diagnose suspected cases at the clinic or hospital,
but results take anywhere from 15 minutes to 8 hours, too slow for
front-line screening.
Analog Devices has an active interest in advancing nanosensor
technology and plans to collaborate with Pinpoint on solutions and
product offerings of mutual benefit to both companies. "Analog Devices
believes Pinpoint's novel nanosensor technology holds great promise for a
wide range of applications, especially for rapid, low-cost pathogen
detection, and we look forward to a long and fruitful collaboration with
Pinpoint in bringing this breakthrough technology to market," commented
Nimrode Moreshet, Director of Emerging Business at Analog Devices.
"We are thrilled to be working with Analog Devices to develop and
manufacture our innovative nanosensor diagnostic platform," commented Lisa Diamond,
CEO of Pinpoint Science. "Our collaboration with a world-class
semiconductor manufacturer like ADI means we can begin to realize the
potential of our groundbreaking technology. We see the immediate
real-world need for our platform, especially with the pandemic threat
posed by the novel coronavirus. Pinpoint's technology can uniquely
address the problem of effective mass screening: sensitive enough to
detect asymptomatic infections, specific enough to distinguish novel
coronavirus from other illnesses, fast enough to replace fever scans,
simple enough to use for home self-testing, and affordable enough to use
anywhere in the world. We are developing a low-cost, high-speed
handheld screening test that can be rapidly deployed as a critical
weapon to address emerging global disease threats."
For more information, please contact:
Angelike Kefalas at (415) 606-2900 or angelike.kefalas@pinpointscience.com
Pinpoint Science Inc. is a San Francisco-based
startup developing a new generation of bioelectronic point-of-care
diagnostics for viral, bacterial and fungal pathogens. Pinpoint's
nanosensors are used to detect biomarkers—antibodies, antigens, toxins,
nucleic acids—to identify specific microbial pathogens. Early targets
include influenza, coronavirus, and STDs. Pinpoint's platform—a handheld
reader and disposable cartridges—is easy to use and affordable, showing
accurate results in under a minute, with no lab, technicians,
amplification or sample prep needed. Visit https://pinpointscience.com/
Analog Devices, Inc. is a leading global high-performance
analog technology company dedicated to solving the toughest engineering
challenges, enabling our customers to interpret the world around us by
intelligently bridging the physical and digital with unmatched
technologies that sense, measure, power, connect and interpret. Visit https://www.analog.com
This release may be deemed to contain forward-looking statements
intended to qualify for the safe harbor from liability established by
the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, among other things, statements
regarding the expected opportunities, benefits, product and service
offerings, and developments associated with the collaboration between
Analog Devices and Pinpoint Science relating to nanosensor diagnostic
solutions, that are based on current expectations, beliefs, assumptions,
estimates, forecasts, and projections about the industry and markets in
which the companies operate. The statements contained in this release
are not guarantees of future performance, are inherently uncertain,
involve certain risks, uncertainties, and assumptions that are difficult
to predict. Therefore, actual outcomes and results may differ
materially from what is expressed in such forward-looking statements,
and such statements should not be relied upon as representing Analog
Devices' expectations or beliefs as of any date subsequent to the date
of this release. Important factors that could cause actual results
to differ materially from the results described, implied or projected in
any forward-looking statements include difficulty or delay in our
design, development, production and marketing of products, technologies
and solutions, including those associated with the collaboration between
Analog Devices and Pinpoint Science, and other risk factors described
in the most recent filings of Analog Devices with the Securities and
Exchange Commission. Analog Devices does not undertake any obligation to
update any forward-looking statements contained in this release
or otherwise.